Literature DB >> 2959307

Salbutamol and ipratropium in partially reversible airway obstruction.

C K Connolly1, N S Chan.   

Abstract

Thirty-six patients with a combination of reversible and persistent airway obstruction were treated with ipratropium bromide, salbutamol and a combination of both in high dose by nebulizer after a control period of rimiterol. The ipratropium and salbutamol were given double blind in random order and the dose of each was the same during the combination periods. Although there was a significant increase in pulmonary function in all treatment periods over the control, only the 6-minute walking distance was significantly improved in the combination period over treatment with salbutamol and ipratropium individually. This was not due to a progressive rise with time irrespective of the therapy. The results are compatible with a small number of patients benefiting from combination therapy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2959307     DOI: 10.1016/0007-0971(87)90108-2

Source DB:  PubMed          Journal:  Br J Dis Chest        ISSN: 0007-0971


  5 in total

1.  Six-minute walking versus shuttle walking: responsiveness to bronchodilation in chronic obstructive pulmonary disease.

Authors:  Véronique Pepin; Julie Brodeur; Yves Lacasse; Julie Milot; Pierre Leblanc; François Whittom; François Maltais
Journal:  Thorax       Date:  2006-11-10       Impact factor: 9.139

2.  Reproducibility of walking test results in chronic obstructive airways disease.

Authors:  A J Knox; J F Morrison; M F Muers
Journal:  Thorax       Date:  1988-05       Impact factor: 9.139

Review 3.  Impact of bronchodilator therapy on exercise tolerance in COPD.

Authors:  B Aguilaniu
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-04-07

4.  Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease.

Authors:  P Moayyedi; J Congleton; R L Page; S B Pearson; M F Muers
Journal:  Thorax       Date:  1995-08       Impact factor: 9.139

5.  Effect of increasing doses of beta agonists on spirometric parameters, exercise capacity, and quality of life in patients with chronic airflow limitation.

Authors:  R Jaeschke; G H Guyatt; A Willan; D Cook; S Harper; J Morris; H Ramsdale; R Haddon; M Newhouse
Journal:  Thorax       Date:  1994-05       Impact factor: 9.139

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.